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To the Editor,
Vaccination against SARS-CoV-2 is one of the most 
important elements to fight against the global pan-
demic of this virus. Implementation of the first vac-
cines against SARS-CoV-2 has been a breakthrough 
that may change the course of the pandemic. Con-
currently, the first reports regarding the adverse re-
actions of vaccines have become available, raising 
concerns about the risk-to-benefit ratio. 
In the study which investigated the efficacy 
and safety of the mRNA-1273 SARS-CoV-2 vaccine 
(Moderna) in 30.420 volunteers, the most fre-
quent adverse effects in the study group included 
pain at the injection site (83.7% in the vaccine 
group vs. 17.5% in the placebo group), fatigue 
(37.2% vs. 27.3%), headache (32.7 vs 26.6%), 
myalgia (22.7% vs. 13.7%), arthralgia (16.6% 
vs. 11.8%), axillary swelling or tenderness (10.2% 
vs 4.8%), chills (8.3% vs. 5.8%), nausea and vom-
iting (8.3% vs. 7.1%), swelling (6.1% vs 0.3%), er-
ythema (2.8% vs. 0.4%) and fever (0.8% vs 0.3%) 
[1]. At the median of 9 weeks after the second vac-
cine dose, serious adverse reactions were reported 
by 1% of the recipients in the vaccine group and 
1% in the placebo group. These reactions included 
one Bell’s palsy and two facial oedemas in patients 
previously undergoing aesthetic medicine inter-
ventions, suggesting allergic background. There 
were no neurologic, thrombotic and inflammato-
ry reactions.
Similarly, in the study evaluating the 
BNT162b2 vaccine (Pfizer) among 43.548 partici-
pants, the most commonly reported reaction was 
mild-to-moderate pain at the injection site. Pain was 
reported less frequently among older participants 
(> 55 years of age; 71% and 66% after the first 
and second dose, respectively) than among younger 
participants (83% and 78% after the first dose and 
second dose, respectively) [2]. The most commonly 
reported systemic events were fatigue and head-
ache (59% and 52% after subsequent doses among 
younger recipients; 51% and 39% among older re-
cipients). However, fatigue and headache were also 
reported by many placebo recipients (23% and 24%, 
after subsequent doses in younger participants; 17% 
and 14% among older recipients). Severe systemic 
events were reported in less than 2% of vaccine re-
cipients after either dose. Fever defined as tempera-
ture ≥ 38°C was reported by 16% of younger vaccine 
recipients and by 11% of older recipients, with the 
temperature mostly below 39°C [3].
The Centres for Disease Control and Prevention 
(CDC) reported that there have been 21 cases of 
anaphylaxis after the BNT162b2 vaccine between 
14 and 23 December 2020 (11.1 cases per 1 million 
doses), with 71% of them occurring within 15 min-
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utes following the vaccination [3]. Twenty of these 
patients (95%) were successfully rescued and only 
1 patient died. The probable cause of anaphylaxis 
was polyethylene glycol (PEG), also called macrogol, 
which is an excipient and lipid facilitating the trans-
port of mRNA-containing nanoparticles into cells 
and allowing for the synthesis of spike-protein — an 
antigen triggering immunity to SARS-CoV-2 [4]. PEG 
is an ingredient of multiple tablets, cosmetics and 
household products. Patients oversensitive to PEG 
usually had repeated systemic allergic reactions/an-
aphylaxis before diagnosis. Also, 81% of patients 
who experienced anaphylaxis after SARS-CoV-2 vac-
cine had known history of allergic reactions to med-
ical products, supporting the hypothesis of allergic 
background underlying anaphylaxis.
Altogether, nearly 90% of patients experience 
any adverse reaction, compared to as much as 50% 
in the placebo group. The vast majority of these 
reactions are mild and resolve within 2 to 3 days. Se-
rious adverse events are rare, and their incidence is 
similar in the vaccine and placebo group. The hith-
erto reported cases of anaphylaxis seem to results 
from oversensitivity to the excipients of the vaccine, 
rather than the vaccine itself. To summarize, the 
available evidence clearly shows that the benefits 
from vaccination substantially overweight the risks 
of COVID-19 disease, especially in the high-risk pop-
ulations. Nevertheless, special caution should be 
taken in patients with established allergy to PEG, 
or a history of allergic reactions to other medica-
tions. Further research is required to evaluate the 
long-term efficacy and safety of the currently availa-
ble COVID-19 vaccines. 
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